Revenue Growth - Revenue increased by $4.4 billion, or 5.5%, from the prior year quarter, driven by growth in both U.S. and International Healthcare Solutions segments [94]. - U.S. Healthcare Solutions revenue rose by $3.7 billion, or 5.0%, primarily due to unit volume growth, including a $1.0 billion increase in sales of GLP-1 products, offset by losses from a grocery and oncology customer [97]. - International Healthcare Solutions revenue increased by $0.7 billion, or 9.6%, mainly due to a $0.5 billion rise in sales at the European distribution business [98]. Profit and Operating Income - Gross profit increased by $514.0 million, or 20.1%, from the prior year quarter, with U.S. Healthcare Solutions gross profit up by $428.8 million, or 29.5% [100]. - Total segment operating income increased by $113.4 million, or 11.9%, with U.S. Healthcare Solutions operating income up by $144.4 million, or 21.0% [94]. - U.S. Healthcare Solutions' operating income increased by $144.4 million, or 21.0%, to $831.3 million, while International Healthcare Solutions' operating income decreased by $23.0 million, or 13.9%, to $142.2 million [114][115]. - Total segment operating income rose by 11.9% to $1.06 billion, driven by gains from antitrust litigation settlements and a LIFO credit [114]. Expenses and Impairments - Total operating expenses rose by $459.8 million, or 24.8%, primarily due to the acquisition of RCA and asset impairment in U.S. Consulting Services [94]. - Distribution, selling, and administrative expenses increased by $323.2 million, or 22.0%, compared to the prior year quarter, primarily due to the acquisition of RCA [106]. - An impairment of assets, including goodwill, of $249.5 million was recorded related to the U.S. Consulting Services business classified as held for sale [113]. Tax and Interest - The effective tax rates were 20.1% for the three months ended December 31, 2025, lower than the U.S. statutory rate due to benefits from lower taxed income and equity compensation [94]. - Interest expense, net increased by $44.5 million, or 159.2%, to $72.4 million, primarily due to the issuance of $1.8 billion in senior notes and a $0.8 billion variable-rate term loan [118]. - Effective tax rates were 20.1% for the three months ended December 31, 2025, compared to 20.4% in the prior year, benefiting from lower tax rates on certain income [119]. Cash Flow and Debt - Cash used in operations decreased by $0.4 billion to $2.3 billion, with significant cash outflows attributed to a $3.5 billion increase in inventories [124][125]. - Total debt as of December 31, 2025, was $7.92 billion, with $7.69 billion in additional credit facility availability [135]. - The company expects future cash flows from operations to be sufficient to meet ongoing cash requirements, including opioid litigation payments over the next 13 years [121]. - Cash and cash equivalents totaled $1.8 billion as of December 31, 2025, with a potential increase in net interest expense due to interest rate changes [154]. Capital Expenditures and Financing - Capital expenditures for the three months ended December 31, 2025, were $119.4 million, up from $105.9 million in the prior year, with plans to invest approximately $900 million in fiscal 2026 [129][130]. - Net cash provided by financing activities was $43.2 million, resulting from $0.3 billion in net borrowings under revolving credit facilities [132]. - A $1.5 billion delayed draw senior unsecured term loan facility was obtained in January 2026 to finance part of the acquisition of OneOncology [141]. - A $3.0 billion delayed draw senior unsecured term loan facility was also secured in January 2026 for the same acquisition [143]. Shareholder Returns and Obligations - The company authorized a share repurchase program of up to $2.0 billion, with $882.2 million available as of December 31, 2025 [147]. - The quarterly dividend was increased by 9% from $0.55 to $0.60 per share, with future dividends dependent on earnings and financial condition [148]. - The accrued litigation liability related to the Distributor Settlement Agreement is $4.3 billion, expected to be paid over the next 13 years [149]. - Total contractual obligations for future principal and interest payments amount to $13.7 billion as of December 31, 2025 [150]. - The company had $1.2 billion of variable-rate debt outstanding as of December 31, 2025 [153].

Key Takeaways COR reported Q1 adjusted EPS of $4.08, beating estimates, while revenue rose 5.5% year over year.Cencora saw 5% U.S. segment revenue growth driven by GLP-1 and specialty drug demand.COR expanded adjusted gross margin by 37 bps and raised FY26 revenue growth guidance to 7-9%.Cencora, Inc. (COR) reported fiscal first-quarter 2026adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $4.07 by 0.2%. The bottom line also improved 9.4% year over year.GAAP EPS was $2.8 ...

Cencora (NYSE:COR) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Company ParticipantsBennett Murphy - SVP, Investor Relations and Enterprise ProductivityBob Motsch - President and CEOElizabeth Anderson - Senior Managing DirectorGeorge Hill - Managing DirectorGlen Santangelo - Managing DirectorJim Cleary - Executive VP and CFOLisa Gill - Managing DirectorMichael Cherny - Senior Managing DirectorSteven Collis - CEOConference Call ParticipantsAllen Lutz - Equity Research AnalystCharles Rhee - Managing Di ...

Cencora (NYSE:COR) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Company ParticipantsBennett Murphy - SVP, Investor Relations and Enterprise ProductivityBob Mauch - President and CEOElizabeth Anderson - Senior Managing DirectorGeorge Hill - Managing DirectorGlen Santangelo - Managing DirectorJim Cleary - Executive VP and CFOLisa Gill - Managing DirectorMichael Cherny - Senior Managing DirectorSteven Collis - CEOConference Call ParticipantsAllen Lutz - Equity Research AnalystCharles Rhee - Managing Dir ...

Cencora (NYSE:COR) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Speaker2It is now my pleasure to hand over to your host, Bennett Murphy, Senior Vice President of Investor Relations and Enterprise Productivity, to begin. Please go ahead.Speaker0Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Cencora's fiscal 2026 first quarter results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob ...

Cencora (COR) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $4.07 per share. This compares to earnings of $3.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.35%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $3.79 per share when it actually produced earnings of $3.84, delivering a surprise of +1.32%.Over the last four quarters, ...

Cencora, Inc. First Quarter Fiscal 2026 Earnings Call February 4, 2026 Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," ...

Cencora on Wednesday beat Wall Street estimates for first-quarter profit, as the drug distributor rode the wave of sustained demand for specialty medicines and GLP-1 therapies. ...

Exhibit 99.1 CENCORA REPORTS FISCAL 2026 FIRST QUARTER RESULTS Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaf irmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology CONSHOHOCKEN, PA, February 4, 2026 - Cencora, Inc. (NYSE: COR) reported that in its fiscal year 20 ...

Form 10-K for the fiscal year ended September 30, 2025 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.CENCORA, INC.FINANCIAL SUMMARY(in thousands, except per share data)(unaudited)Three MonthsEndedDecember 31, 2025% ofRevenueThree MonthsEndedDecember 31, 2024% ofRevenue%ChangeRevenue$85,932,01 ...